The Canadian government has cleared KGK Science's Phase 2a trial testing NM-1001, a psilocybin microdose therapy, in fragile X syndrome.| Fragile X News Today
Recruitment of adults with fragile X syndrome to test NM-1001, a microdose of the psychedelic psilocybin is ongoing in Ontario, Canada.| Fragile X News Today